Skip to main content
Equibles
OKUR logo

OKUR · OnKure Therapeutics, Inc. · Metrics

Track OKUR — free

Use OKUR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OKUR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.51 -0.09 (-3.47%)
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared Aug 4, 2026

The latest filing states the doubt was alleviated.

“As of December 31, 2025, the Company had determined that substantial doubt about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist. However, following completion of the 2026 Private Placement (see Note 9), management believes the Company's cash, cash equivalents and marketable securities will be sufficient to fund its current operating plan for at least the next 12 months from the date of issuance of these condensed consolidated financial statements and as such substantial doubt has been alleviated.”
View the 10-Q filed Aug 4, 2026
Market Cap
$105.09M
Shares
40.50M
Volume · Oct 28 72.7K Avg daily vol (3M) 255.87K

OKUR metrics

70 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.60
Market cap
$105.09M

Price action

20 metrics
Price change (1W)
+10.0%
Price change (30D)
-6.0%
Price change (3M)
-34.3%
Price change (6M)
-50.3%
Price change (YTD)
-10.5%
Price change (1Y)
-27.3%
Trailing year
Price change (5Y)
—
52-week high
$5.27
52-week low
$2.10
Change from 52-week high
-50.8%
Change from 52-week low
+23.6%
Annualized volatility
70.3%
Annualized volatility (3M)
56.3%
Beta
1.2
RSI (14D)
50.0
Price vs SMA 50
-13.3%
Price vs SMA 200
-28.3%
Avg volume (3M)
255,865
Relative volume
1.3
Average dollar volume
$748,806

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
40.50M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.6
reciprocal yield 171.7%
FCF yield
-47.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-58.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$62.14M
Net income (TTM)
−$58.70M
Trailing 12 months
Diluted EPS (TTM)
$-3.49
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-3.67
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-3.50
Operating cash flow per diluted share (TTM)
$-2.96
Free cash flow per diluted share (TTM)
$-2.97
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$2.78
Stock compensation per diluted share (TTM)
$0.71
Book value per share
$-40.39

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+269.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-34.1%
Return on assets
-32.7%
Debt / equity
0.0
Current ratio
26.7
EBITDA (TTM)
−$61.74M
Free cash flow (TTM)
−$47.86M
Quick ratio
26.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$166.50M
Latest balance sheet
Cash & equivalents
$166.50M
Total assets
$179.35M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$47.84M
Capital expenditures (TTM)
$23,000
R&D (TTM)
$46.95M
SG&A (TTM)
—
Stock compensation (TTM)
$11.81M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
75
13F filer change QoQ
+24
Institutional ownership
86.1%
Conviction holders (share of 13F filers)
2.7%
Crowding (high-turnover and private-fund holders)
51.3%
Private-fund adviser ownership
45.7%
Active holders' share change QoQ
+12.2%
Holder tenure
3.9
Price vs estimated holder cost
+31.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
6.0%

Short interest

3 metrics
Short interest
3.4%
Latest settlement · 2.6 days to cover
Days to cover
2.6d
Short-squeeze score
51 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1,157
Insider-sentiment score
51 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1637715 CUSIP 68277Q105 13F (30d) 3 filings 3 filers Visit website Investor relations